A Comparison of Parenteral Sulbactam/Ampicillin versus Clindamycin/Gentamicin in the Treatment of Pelvic Inflammatory Disease
- 10 Downloads
60 hospitalised patients with pelvic inflammatory disease entered a randomised study to compare the therapeutic efficacy and tolerability of parenteral sulbactam/ampicillin with that of clindamycin/gentamicin. All 49 pathogens isolated at entry from 21 evaluable patients in the sulbactam/ampicillin group were eradicated. 34 out of 35 pathogens isolated from 18 evaluable patients in the clindamycin/gentamicin group were eradicated. All pathogens resistant to ampicillin in vitro were eradicated. The bacteriological, clinical and overall responses for the sulbactam/ampicillin group were 100%, 85.7% and 85.7%, respectively, compared with 97.1%, 94.4% and 94.4%, respectively, for the clindamycin/gentamicin group. The sulbactam/ampicillin combination was well tolerated.
KeywordsClindamycin Chlamydia Trachomatis Pelvic Inflammatory Disease Glycogen Storage Disease Neisseria Gonorrhoeae
Unable to display preview. Download preview PDF.
- Sweet RL, Draper DL, Schachter J, James J, Hadley WK, et al.: Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample? American J Obstet Gynecol 138: 985–989, 1980Google Scholar